439 related articles for article (PubMed ID: 25697595)
21. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception.
Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L
Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442
[TBL] [Abstract][Full Text] [Related]
22. Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study.
Nakano T; Tanaka S; Tsuruya K; Kitazono T
Clin Exp Nephrol; 2021 Apr; 25(4):385-393. PubMed ID: 33398604
[TBL] [Abstract][Full Text] [Related]
23. Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism.
Chen H; Chen L; Liu D; Chen DQ; Vaziri ND; Yu XY; Zhang L; Su W; Bai X; Zhao YY
J Proteome Res; 2017 Apr; 16(4):1566-1578. PubMed ID: 28286957
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
25. Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease.
Khandelwal P; Murugan V; Hari S; Lakshmy R; Sinha A; Hari P; Bagga A
Pediatr Nephrol; 2016 Aug; 31(8):1313-20. PubMed ID: 26921213
[TBL] [Abstract][Full Text] [Related]
26. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers.
Chhatrala R; Siddiqui MB; Stravitz RT; Driscoll C; Sanyal A; Sargeant C; Luketic V; Sharma A; Sterling R; Matherly S; Puri P; Siddiqui MS
Liver Transpl; 2015 May; 21(5):623-30. PubMed ID: 25762084
[TBL] [Abstract][Full Text] [Related]
27. Role of Leptin and dyslipidemia in chronic kidney disease.
Noor S; Alam F; Fatima SS; Khan M; Rehman R
Pak J Pharm Sci; 2018 May; 31(3):893-897. PubMed ID: 29716870
[TBL] [Abstract][Full Text] [Related]
28. Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Shah R; Matthews GJ; Shah RY; McLaughlin C; Chen J; Wolman M; Master SR; Chai B; Xie D; Rader DJ; Raj DS; Mehta NN; Budoff M; Fischer MJ; Go AS; Townsend RR; He J; Kusek JW; Feldman HI; Foulkes AS; Reilly MP;
Am J Kidney Dis; 2015 Aug; 66(2):266-73. PubMed ID: 25795074
[TBL] [Abstract][Full Text] [Related]
29. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5.
Chiu H; Wu PY; Huang JC; Tu HP; Lin MY; Chen SC; Chang JM
Sci Rep; 2020 Jul; 10(1):12749. PubMed ID: 32728174
[TBL] [Abstract][Full Text] [Related]
30. Dyslipidemia in Patients with Kidney Disease.
Thobani A; Jacobson TA
Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania.
Vlad CE; Foia L; Pavel-Tanasa M; Toma V; Florea L; Voroneanu L; Apetrii M; Dodi G; Covic A
Int Urol Nephrol; 2022 Mar; 54(3):647-659. PubMed ID: 34224064
[TBL] [Abstract][Full Text] [Related]
32. Dyslipidemia in patients with chronic kidney disease.
Hager MR; Narla AD; Tannock LR
Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
[TBL] [Abstract][Full Text] [Related]
33. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
34. Early markers of cardiovascular risk in chronic kidney disease.
Lai S; Dimko M; Galani A; Coppola B; Innico G; Frassetti N; Mazzei ED; Mariotti A
Ren Fail; 2015 Mar; 37(2):254-61. PubMed ID: 25394527
[TBL] [Abstract][Full Text] [Related]
35. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
Sonmez A; Yilmaz MI; Saglam M; Unal HU; Gok M; Cetinkaya H; Karaman M; Haymana C; Eyileten T; Oguz Y; Vural A; Rizzo M; Toth PP
Lipids Health Dis; 2015 Apr; 14():29. PubMed ID: 25885289
[TBL] [Abstract][Full Text] [Related]
36. Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease.
Savic J; Zeljkovic A; Bogavac-Stanojevic N; Simic-Ogrizovic S; Kravljaca M; Stosovic M; Vekic J; Spasojevic-Kalimanovska V; Jelic-Ivanovic Z; Gojkovic T; Spasic S
Scand J Clin Lab Invest; 2014 Oct; 74(7):637-43. PubMed ID: 24958359
[TBL] [Abstract][Full Text] [Related]
37. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease.
Chan DT; Watts GF; Irish AB; Ooi EM; Dogra GK
Am J Hypertens; 2013 Sep; 26(9):1155-61. PubMed ID: 23736110
[TBL] [Abstract][Full Text] [Related]
38. Serum magnesium is inversely associated with coronary artery calcification in the Genetics of Atherosclerotic Disease (GEA) study.
Posadas-Sánchez R; Posadas-Romero C; Cardoso-Saldaña G; Vargas-Alarcón G; Villarreal-Molina MT; Pérez-Hernández N; Rodríguez-Pérez JM; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG; Torres-Tamayo M
Nutr J; 2016 Mar; 15():22. PubMed ID: 26931571
[TBL] [Abstract][Full Text] [Related]
39. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
40. The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.
Rysz J; Gluba-Brzózka A; Rysz-Górzyńska M; Franczyk B
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
